Evrofarma SA (EVROF.AT)
EUR 1.63
(0.93%)
EUR 1.63
(0.93%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.2 Million EUR | 55.18% |
| 2022 | 1.41 Million EUR | 499.72% |
| 2021 | -355 Thousand EUR | -132.87% |
| 2020 | 1.08 Million EUR | 587.9% |
| 2019 | 157 Thousand EUR | -83.96% |
| 2018 | 979 Thousand EUR | 82.65% |
| 2017 | 536 Thousand EUR | 30.1% |
| 2016 | 412 Thousand EUR | -21.82% |
| 2015 | 527 Thousand EUR | 288.21% |
| 2014 | -280 Thousand EUR | 29.65% |
| 2013 | -398 Thousand EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.4 Million EUR | 0.0% |
| 2023 Q3 | 393 Thousand EUR | -44.49% |
| 2023 FY | 2.2 Million EUR | 55.18% |
| 2023 Q1 | 708 Thousand EUR | -1.73% |
| 2023 Q2 | 708 Thousand EUR | 0.0% |
| 2023 Q4 | 393 Thousand EUR | 0.0% |
| 2022 Q4 | 720.5 Thousand EUR | 0.0% |
| 2022 Q3 | 720.5 Thousand EUR | 6650.0% |
| 2022 Q1 | -11 Thousand EUR | 97.83% |
| 2022 FY | 1.41 Million EUR | 499.72% |
| 2022 Q2 | -11 Thousand EUR | 0.0% |
| 2021 FY | -355 Thousand EUR | -132.87% |
| 2021 Q1 | 330 Thousand EUR | -55.53% |
| 2021 Q4 | -507.49 Thousand EUR | 0.0% |
| 2021 Q2 | 660 Thousand EUR | 100.0% |
| 2021 Q3 | -507.49 Thousand EUR | -176.89% |
| 2020 Q4 | 742 Thousand EUR | 105.83% |
| 2020 FY | 1.08 Million EUR | 587.9% |
| 2020 Q2 | 338 Thousand EUR | 100.0% |
| 2020 Q1 | 169 Thousand EUR | 364.06% |
| 2020 Q3 | 360.5 Thousand EUR | 6.66% |
| 2019 Q2 | 221 Thousand EUR | 100.0% |
| 2019 FY | 157 Thousand EUR | -83.96% |
| 2019 Q4 | -64 Thousand EUR | -100.0% |
| 2019 Q3 | -32 Thousand EUR | -114.48% |
| 2019 Q1 | 110.5 Thousand EUR | -34.23% |
| 2018 Q3 | 168 Thousand EUR | -47.74% |
| 2018 FY | 979 Thousand EUR | 82.65% |
| 2018 Q4 | 168 Thousand EUR | 0.0% |
| 2018 Q2 | 321.5 Thousand EUR | 0.0% |
| 2018 Q1 | 321.5 Thousand EUR | 142.64% |
| 2017 Q2 | 135.5 Thousand EUR | 0.0% |
| 2017 FY | 536 Thousand EUR | 30.1% |
| 2017 Q3 | 132.5 Thousand EUR | -2.21% |
| 2017 Q4 | 132.5 Thousand EUR | 0.0% |
| 2017 Q1 | 135.5 Thousand EUR | 41.15% |
| 2016 FY | 412 Thousand EUR | -21.82% |
| 2016 Q2 | 110 Thousand EUR | 0.0% |
| 2016 Q1 | 110 Thousand EUR | 225.0% |
| 2016 Q4 | 96 Thousand EUR | 0.0% |
| 2016 Q3 | 96 Thousand EUR | -12.73% |
| 2015 Q4 | -88 Thousand EUR | -130.66% |
| 2015 FY | 527 Thousand EUR | 288.21% |
| 2015 Q3 | 287 Thousand EUR | 160.91% |
| 2015 Q2 | 110 Thousand EUR | -49.54% |
| 2015 Q1 | 218 Thousand EUR | 199.54% |
| 2014 FY | -280 Thousand EUR | 29.65% |
| 2014 Q2 | -94 Thousand EUR | 63.98% |
| 2014 Q3 | 294 Thousand EUR | 412.77% |
| 2014 Q4 | -219 Thousand EUR | -174.49% |
| 2014 Q1 | -261 Thousand EUR | -247.46% |
| 2013 Q2 | -319 Thousand EUR | -98.14% |
| 2013 Q3 | -95 Thousand EUR | 70.22% |
| 2013 Q1 | -161 Thousand EUR | 0.0% |
| 2013 FY | -398 Thousand EUR | 0.0% |
| 2013 Q4 | 177 Thousand EUR | 286.32% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Flour Mills Kepenos S.A. | 623.67 Thousand EUR | -253.07% |
| Kri-Kri Milk Industry S.A. | 32.26 Million EUR | 93.176% |
| Loulis Food Ingredients S.A. | 6.26 Million EUR | 64.847% |